EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction (EGEVE)
EG-VEGF (Endocrine Gland-derived Vascular Endothelial Growth Factor) in Normal and Pathological Pregnancies: Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Listed as NCT01490489, this NA trial focuses on Intra-uterine Growth Retardation and Pre-eclampsia and remains completed. Sponsored by Institut National de la Santé Et de la Recherche Médicale, France, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Dec 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Oct 2021 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2021 — Oct 2021 [monthly]
Unknown Status NA
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status NA
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut National de la Santé Et de la Recherche Médicale, France
For direct contact, visit the study record on ClinicalTrials.gov .